The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 939 GLP-1 Medications articles
Eli Lilly posted blockbuster Q4 2025 results with $19.29B revenue, yet shares near $1,020 face selling pressure from compounded semaglutide competition and government pricing initiatives. Hims & Hers' $49 pill undercuts Zepbound's $299 intro dose, signaling shifts in the GLP-1 market. Investors eye Orforglipron's FDA decision amid pipeline cuts.
Hims & Hers launched a $49-a-month compounded version of Novo Nordisk's Wegovy, promising affordable GLP-1 weight-loss treatment amid shortages. Yet, despite an initial 14% stock surge, shares closed down 4% as FDA scrutiny loomed. This move highlights tensions in the booming obesity drug market and accessibility challenges for patients.
Novo Nordisk's shares rebounded 4.7% in early trading on Friday after the FDA vowed to crack down on companies mass-marketing illegal copies of Wegovy. This followed a sharp sell-off triggered by Hims & Hers' launch of a cheap $49 compounded version. Understand the safety risks and what this means for GLP-1 patients seeking approved weight-loss treatments.
As millions use GLP-1 medications like Ozempic for weight loss, clinicians are seeing a rise in new eating disorders dubbed 'agonorexia.' These drugs' powerful appetite suppression may drive dangerous food and body image obsessions, even in those without prior history. Experts warn current screening may miss at-risk patients.
Super Bowl LX is set to showcase a surge in GLP-1 weight-loss drug ads from telehealth giants like Ro featuring Serena Williams and Novo Nordisk's Ozempic and Wegovy. With record $8-10M ad slots, health trends dominate alongside AI and celebrity-packed spots with George Clooney and Kendall Jenner. This 'GLP-1 Super Bowl' highlights booming demand for metabolic health solutions.
Super Bowl LX ads are packed with celebrities from Kendall Jenner to George Clooney, cutting-edge AI demos, and a surge in health spots promoting GLP-1 weight-loss drugs like Ozempic and Wegovy. As viewership hits record highs, advertisers are betting big on telehealth and pharma amid booming demand. This preview reveals the trends shaping America's biggest ad showdown.
Shares in Novo Nordisk, maker of Ozempic and Wegovy, plunged 18% after a sales warning flagged up to 13% decline in the US market due to falling GLP-1 drug prices. Despite 2025 sales growth of 6% to 309 billion kronor, the stock wipeout erased $32 billion in value. CEO Mike Doustdar highlights the upcoming Wegovy pill as a key future driver.
New topline data from the REIMAGINE 2 trial reveal CagriSema outperforms semaglutide in HbA1c reduction and weight loss for adults with type 2 diabetes inadequately controlled on metformin. Patients on CagriSema 2.4mg/2.4mg saw a 1.91% point HbA1c drop and 14.2% body weight loss at 68 weeks. This combination of cagrilintide and semaglutide sets a new benchmark in T2D therapy.
Jason Krynicki, once bullied for obesity, now battles anorexia while on Zepbound, fearing weight regain if he stops. GLP-1 drugs curb appetite effectively but complicate lives for those with disordered eating, often without proper screening. Experts highlight risks and call for caution in a weight-stigma culture.
